Uli C. Broedl

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. · Circulation · 2013 · 1.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Ele Ferrannini, Elza Muscelli, Silvia Frascerra et al. · Journal of Clinical Investigation · 2014 · 1.1K citations · Full text

Medicine, Endocrinology, Physiology +11

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

Anthony Barnett, Ambrish Mithal, Jenny Manassie et al. · The Lancet Diabetes & Endocrinology · 2014 · 575 citations

Medicine, Pharmacology, Pharmacotherapy +14